Management Board of Selvita S.A. with its registered office in w Krakow (“Issuer”) in reference to the current report no. 37/2020 dated 23 November 2020 hereby announces, that today, after the fulfilment of all conditions precedent, including in particular:

i) extension of the lease agreement concluded between Fidelta d.o.o. (“Fidelta”) and Pliva Hrvatska d.o.o. concerning office and laboratory space, until 31 December 2027,

ii) conclusion by Fidelta of a pre-lease agreement with Medi-Lab d.o.o. and Emo Mancipo d.o.o. concerning rental of additional office and laboratory space,

Issuer, as the buyer, concluded an definitive agreement with Galapagos NV with its registered office in Mechelen (Belgium), as the seller, concerning purchase of 100% of Fidelta’s shares for the price of  EUR 31.200.000 (PLN 141.913.000; EUR/PLN exchange rate: 1 EUR= 4,5485 PLN) (“Transaction”). The purchase price will be adjusted for net cash and working capital in accordance to the customary provisions that are used in this type of agreements. The purchase price for the shares was covered with Issuer’s own funds in the amount of EUR 9,360,000 and with the bank loan in the amount of EUR 21,840,000, about which the Issuer informed in the current report no. 40/2020, dated 21 December 2020.

The Transaction constitutes Selvita Capital Group’s long-term investment of a strategic nature and at the same time is a transformative step in the implementation of the Issuer’s Capital Group’s Strategy for years 2020-2023, which was adopted on 29 April 2020.

Legal basis:

Art. 17 par. 1 of MAR

Representatives of the Company:     

  • Bogusław Sieczkowski – President of the Management Board
  • Dawid Radziszewski – Management Board Member